Onpattro (Patisiran)

Patisiran is a small interfering RNA (siRNA) delivered in a lipid nanoparticle. After intravenous infusion, it enters liver cells and joins the RNA‑induced silencing complex, where it binds to transthyretin messenger RNA. This binding leads to degradation of the mRNA, preventing translation and markedly lowering circulating transthyretin levels.

The dosing regimen for Onpattro is determined by the prescribing physician based on the patient’s weight, disease severity, and clinical response. The prescriber sets the exact dose and infusion schedule, which is typically administered every three weeks under medical supervision.

Data on the use of Onpattro in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment and for a period after the last dose.

To request Onpattro, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and the necessary import documentation.

Onpattro is an RNAi‑based therapy that reduces transthyretin production at the genetic level, whereas other options such as tafamidis stabilize the TTR protein and diflunisal act as kinetic stabilizers. The choice depends on disease stage, organ involvement, patient tolerance, and physician assessment of efficacy and safety profiles.

Onpattro must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Prior to infusion, the solution is allowed to reach room temperature as directed by the product label.

Onpattro is given as an intravenous infusion, typically over about 80 minutes, once every three weeks. The infusion is performed in a clinical setting where healthcare professionals can monitor the patient for any infusion‑related reactions and manage them promptly.

Serious risks include severe hypersensitivity reactions (including anaphylaxis), significant elevations in liver enzymes indicating hepatic injury, and thrombocytopenia that can lead to bleeding complications. Patients should be monitored closely for these events throughout treatment.

Onpattro is contraindicated in individuals with known hypersensitivity to patisiran, its lipid nanoparticle components, or any excipients in the formulation. Caution is also advised for patients with severe hepatic impairment, uncontrolled cardiac disease, or those who are pregnant without a clear benefit‑risk justification.